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Summary
Background: The 2014 Zaire Ebola virus disease epidemic accelerated vaccine development for the virus. We aimed to 
assess the safety, reactogenicity, and immunogenicity of one dose of monovalent, recombinant, chimpanzee 
adenovirus type-3 vectored Zaire Ebola glycoprotein vaccine (ChAd3-EBO-Z) in adults.
Methods This phase 2, randomised, observer-blind, controlled trial was done in study centres in Cameroon, Mali, 
Nigeria, and Senegal. Healthy adults (≥18 years) were randomly assigned with a web-based system (1:1; minimisation 
procedure accounting for age, gender, centre) to receive ChAd3-EBO-Z (day 0), or saline placebo (day 0) and 
ChAd3-EBO-Z (month 6). The study was observer-blind until planned interim day 30 analysis, single-blind until 
month 6, and open-label after month 6 vaccination. Primary outcomes assessed in the total vaccinated cohort, 
which comprised all participants with at least one study dose administration documented, were serious adverse 
events (up to study end, month 12); and for a subcohort were solicited local or general adverse events (7 days post-
vaccination), unsolicited adverse events (30 days post-vaccination), haematological or biochemical abnormalities, 
and clinical symptoms of thrombocytopenia (day 0–6). Secondary endpoints (subcohort; per-protocol cohort) 
evaluated anti-glycoprotein Ebola virus antibody titres (ELISA) pre-vaccination and 30 days post-vaccination. This 
study is registered with ClinicalTrials.gov, NCT02485301.
Findings Between July 22, 2015, and Dec 10, 2015, 3030 adults were randomly assigned; 3013 were included in the total 
vaccinated cohort (1509 [50·1%] in the ChAd3-EBO-Z group and 1504 [49·9%] in the placebo/ChAd3-EBO-Z group), 
17 were excluded because no vaccine was administered. The most common solicited injection site symptom was pain 
(356 [48%] of 748 in the ChAd3-EBO-Z group vs 57 [8%] of 751 in the placebo/ChAd3-EBO-Z group); the most 
common solicited general adverse event was headache (345 [46%] in the ChAd3-EBO-Z group vs 136 [18%] in the 
placebo/ChAd3-EBO-Z group). Unsolicited adverse events were reported by 123 (16%) of 749 in the ChAd3-EBO-Z 
group and 119 (16%) of 751 in the placebo/ChAd3-EBO-Z group. Serious adverse events were reported for 11 (1%) of 
1509 adults in the ChAd3-EBO-Z group, and 18 (1%) of 1504 in the placebo/ChAd3-EBO-Z group; none were 
considered vaccination-related. No clinically meaningful thrombocytopenia was reported. At day 30, anti-glycoprotein 
Ebola virus antibody geometric mean concentration was 900 (95% CI 824–983) in the ChAd3-EBO-Z group. There 
were no treatment-related deaths.
Interpretation ChAd3-EBO-Z was immunogenic and well tolerated in adults. Our findings provide a strong basis for 
future development steps, which should concentrate on multivalent approaches (including Sudan and Marburg 
strains). Additionally, prime-boost approaches should be a focus with a ChAd3-based vaccine for priming and boosted 
by a modified vaccinia Ankara-based vaccine.
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Introduction
Ebola virus disease is a serious illness with a case fatality 
rate between 25% and 90%.1 The Ebola virus genus 
contains five distinct species of filoviruses. The Zaire 
Ebola virus was responsible for the largest 2014–16 Ebola 
virus disease epidemic: 28 616 Ebola virus disease cases 
were reported in Guinea, Liberia, and Sierra Leone, of 
which 11 310 were fatal.2
The risk of re-emergence of Ebola virus disease is 
illustrated by the 2017 and 2018–19 outbreaks in the 
Democratic Republic of the Congo.3 A well tolerated and 
effective single-dose Ebola vaccine able to elicit rapid 
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protection would be a crucial tool to control 
future epidemics.4 Current efforts target the Ebola 
virus glycoprotein.5 Candidate DNA vaccines,6–9 Ebola 
virus glycoprotein nanoparticle vaccine,10 and candidate 
vaccines in which viral glycoprotein is expressed through 
various recombinant viral vectors have shown promising 
results in non-human primate models of Ebola 
virus disease11–14 and in early phase clinical trials.5,15–19 
Recombinant vesicular stomatitis virus-based vaccine 
expressing Ebola virus surface glycoprotein (rVSV-
ZEBOV) showed efficacy in a phase 3 ring vaccination 
trial in Guinea20 and was granted conditional marketing 
authorisation by the European Medicines Agency in 
October, 2019.21
The investigational chimpanzee adenovirus type-3 
(ChAd3)-vectored vaccine used in the present study, 
ChAd3-EBO-Z, is based on a replication-defective 
chimpanzee-derived adenovirus technology and contains 
a DNA fragment encoding Ebola virus glycoprotein. 
A single dose of 1 × 10¹¹ particle units of ChAd3-EBO-Z 
provided 100% protection 4–5 weeks post-vaccination in 
a non-human primate model of Ebola infection.14 Overall, 
the vaccine was well tolerated in phase 1 trials.22–24 In 
some cases, thrombocyte counts transiently decreased, 
but no clinical signs or symptoms reported by participants 
suggested an increased tendency to bleed.22–24
This phase 2, randomised, placebo-controlled trial 
aimed to evaluate safety, reactogenicity, and immuno-
genicity following a single intramuscular dose of 
ChAd3-EBO-Z in adults in Africa and was evaluated in 
parallel in a phase 2 trial in children and adolescents in 
Mali and Senegal.25
Methods
Study design and participants
We did a phase 2, randomised, parallel-group, placebo-
controlled, multicentre study at six centres in Africa: two in 
Cameroon, one in Mali, one in Nigeria, and two in Senegal 
Research in context
Evidence before this study
We searched PubMed for clinical trials assessing Ebola vaccines 
from database inception up to Oct 14, 2019, with the title or 
abstract search terms “Ebola” AND “vaccine” AND “trial”. 
No language restrictions or inclusion and exclusion criteria were 
applied. Four phase 1 clinical trials (assessing two DNA vaccines 
and one recombinant adenovirus serotype 5 vaccine) were done 
before 2014. All clinical trials evaluating the chimpanzee 
adenovirus type-3 vectored Zaire Ebola glycoprotein vaccine 
(ChAd3-EBO-Z) were prompted by the 2014–16 epidemic 
assessing various doses and further evaluating its safety and 
reactogenicity. Other viral vector-based vaccines evaluated after 
onset of the epidemic in 2014 included: rVSV-ZEBOV 
(a recombinant vesicular stomatitis virus-vectored vaccine 
expressing a Zaire Ebola virus glycoprotein); recombinant 
adenovirus type-5 (rAd5) vector or type-26 (rAd26) 
vector-based vaccines expressing the glycoprotein of the 2014 
epidemic strain; modified vaccinia Ankara (MVA)-BN-Filo 
(a MVA vector vaccine encoding glycoproteins from Ebola virus, 
Sudan virus, and Marburg virus, as well as nucleoprotein from 
Tai Forest virus); MVA-EBO-Z (a recombinant, replication-
deficient, attenuated vaccinia Ankara virus vector expressing the 
wild-type Ebola glycoprotein of the Zaire Mayinga strain); 
and GamEvac Combi (a vaccine consisting of rVSV and rAd5 
expressing the envelope glycoprotein of the 2014 epidemic 
strain). Efficacy has only been evaluated and observed for the 
rVSV-ZEBOV in a phase 3 ring vaccination trial. Further efficacy 
assessments could not be done because of the end of the 
epidemic. So far, rVSV-ZEBOV is the only licensed vaccine.
Added value of this study
This is the largest trial with the ChAd3-EBO-Z investigational 
vaccine reported to date, to our knowledge. In this phase 2 study, 
we provided a comprehensive assessment of the vaccine, 
evaluating its safety, reactogenicity, and immunogenicity in 
terms of antibody response against Ebola virus glycoprotein, 
Ebola virus glycoprotein-specific T-cell response, and neutralising 
antibody response against the Ebola virus and ChAd3 vector. 
We found that the ChAd3-EBO-Z vaccine candidate had an 
acceptable safety and reactogenicity profile, in line with 
observations from phase 1 studies. In the phase 1 studies, 
transient decreases in thrombocyte counts had been observed; 
although not clinically meaningful, these observations were 
regarded as a potential safety signal. In the current phase 2 study, 
we did not observe meaningful trends towards decreased 
thrombocyte counts after vaccination, and no cases of clinically 
meaningful thrombocytopenia were observed within 7 days after 
vaccination. Antibody response against Ebola virus glycoprotein 
was induced after one dose, confirming observations from the 
phase 1 studies, and persisted up to 12 months post-vaccination. 
We also observed some polyfunctional Ebola virus-specific CD4+ 
and CD8+ T-cell responses.
Implications of all the available evidence
Several regimens of vaccine candidates against Ebola virus in 
clinical evaluation proved to have an acceptable safety profile 
and induced antibody responses. Safety data available to date 
support the clinically acceptable safety and reactogenicity profile 
of the investigational ChAd3-EBO-Z vaccine. We showed the 
immunogenicity of the vaccine with a single vaccination 
approach. The induced anti-glycoprotein Ebola virus 
immunoglobulin G amounts were substantial, although lower 
than those elicited by rVSV-ZEBOV 1 month post-vaccination 
(PREVAIL study) for which vaccine efficacy was observed. It was 
previously shown that ChAd3-EBO-Z vaccine is protective in a 
non-human primate model at the same dose as used in the 
current study. Although all available evidence concerning the 
protective potential of the vaccine against Ebola virus is indirect, 
data collected in the current phase 2 study will be useful in the 
development of similar vaccines against other Ebola strains.
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(appendix p 2). Eligible participants were healthy adults 
(≥18 years), as established by clinical examination at 
enrolment. Exclusion criteria included previous vaccination 
with investigational Ebola or Marburg vaccine, or a chimp-
anzee adenovirus-vectored vaccine; known previous Ebola 
virus or Ebola Sudan virus disease; travel to a country 
affected by the Ebola virus epidemic or direct contact with a 
person with Ebola virus disease within 21 days before the 
day 0 visit; and presence of any immunodeficiency state or 
any acute or chronic disease that was not well controlled, 
which could increase the risk for serious adverse events or 
could impair interpretation of the data. Fully detailed 
inclusion and exclusion criteria are provided in the 
appendix (p 1).
The study followed good clinical practice principles 
and the Declaration of Helsinki, with approval from 
national independent ethics committees (appendix p 1). 
Participants or their legally acceptable representatives 
provided written or thumb-printed informed consent. 
Participants younger than 21 years residing in Cameroon 
provided written or thumb-printed informed assent. 
Ten adult participants had an invalid informed consent 
form that could not be corrected and were excluded from 
all analyses; two participants (one in each group) had 
received the first dose. A protocol summary is available 
online.
Randomisation and masking
Participants were randomly assigned (1:1) at day 0 to the 
ChAd3-EBO-Z or placebo/ChAd3-EBO-Z group, using a 
central interactive response system. This interactive 
response system gave exclusive unmasked treatment 
information access to the unmasked centre personnel. 
The randomisation algorithm used a minimisation 
procedure accounting for age (18–40 years, 41–60 years, 
and >60 years), gender, and centre. Minimisation factors 
had equal weight in the minimisation algorithm. The 
determinism threshold was set at 80% (20% random 
allocation).
The study was observer-blind from study start until 
the planned interim day 30 analysis. Vaccine or placebo 
preparation and administration were done by authorised 
medical personnel who did not participate in any of the 
study clinical evaluation procedures. The study became 
single-blind (only the participant was unaware of treat-
ment assignment) as of interim analysis until vaccination 
of the placebo/ChAd3-EBO-Z group at month 6, and 
open-label after month 6 vaccination. Some of the 
month 6 vaccinations occurred before the planned 
interim analysis, leading to unmasking. For these 
participants, it was ensured that the analysis of the day 
0–30 data for interim analysis had been appropriately 
completed before unmasking.
Procedures
The ChAd3-EBO-Z group received ChAd3-EBO-Z at day 0; 
the placebo/ChAd3-EBO-Z group received placebo at 
day 0 and ChAd3-EBO-Z at month 6. Total study duration 
was approximately 12 months for each participant 
(figure 1). To obtain early data for ChAd3-EBO-Z in the 
context of accelerated vaccine development, a planned 
interim analysis was done when safety, reactogenicity, and 
immunogenicity data from all participants were available 
up to 30 days post-day 0 vaccination (data not shown). 
After this planned interim analysis, the study continued 
as planned.
ChAd3-EBO-Z consists of a recombinant replication-
deficient adenovirus chimpanzee serotype 3 vector 
expressing wild-type Ebola virus glycoprotein from the 
Zaire Mayinga strain (dose 1 × 10¹¹ particle units). The 
placebo control was phosphate-buffered saline. Study 
doses were administered intramuscularly in the deltoid 
of the non-dominant arm.
All participants were followed-up for serious adverse 
events throughout the study. Pregnancies and known 
pregnancy outcomes occurring during the study were 
recorded. A subcohort was followed-up during 7-day 
periods post-vaccination for solicited adverse events and 
30-day periods post-vaccination for unsolicited adverse 
events. This subcohort included the first 750 participants 
enrolled in each group. Whole blood for analysis of 
laboratory safety parameters was drawn from all parti-
cipants at screening, and from the subcohort for follow-
up of adverse events at days 3, 6, 30, month 6, and 
month 12. Participants from the subcohort for follow-up 
of adverse events of the placebo/ChAd3-EBO-Z group 
had additional blood draws at month 6 +6 days and 
month 6 +30 days (figure 1, appendix p 3).
Because of transient non-clinically meaningful drops 
in thrombocyte counts observed in phase 1 trials, signs of 
clinically meaningful thrombocytopenia (ie, abnormal 
bleeding or increased tendency to bleed) starting within 
7 days post-day 0 vaccination were assessed in the current 
study subcohort as an adverse event of special interest.
Anti-glycoprotein Ebola virus IgG antibody response 
was assessed by ELISA in the subcohort for adverse 
events. A blood sample was drawn at days 0 and 30, 
month 6, month 6 +30 days, and month 12 (figure 1). 
Serum was separated and frozen at –20°C. Antibody 
concentrations were determined using the Filovirus 
Animal Non-clinical Group ELISA at Q² Laboratories 
(San Juan Capistrano, CA, USA; appendix p 3). The 
technical cutoff was 36·11 ELISA units (EU)/mL, on the 
basis of the assay’s lower limit of quantification. Antibody 
concentrations less than the cutoff were seronegative and 
given an arbitrary value of half the cutoff for geometric 
mean concentration calculation. Anti-glycoprotein anti-
body response was defined as a three-fold increase 
compared with baseline for participants with baseline 
concentrations of 36·11 EU/mL or more, or post-baseline 
sero conversion for baseline-seronegative participants. 
Sero conversion was defined as the appearance of anti-
bodies (concentrations ≥36·11 EU/mL) in the serum of 
participants who were seronegative before vaccination.
For the protocol summary see 
https://www.gsk-studyregister.
com/en/trial-details/?id=202091
See Online for appendix
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Additional immunological responses were evaluated in 
a subcohort, in which the first 100 enrolled participants 
per group were planned for Ebola virus glycoprotein-
specific cell-mediated immunity and ChAd3 neutralising 
antibody (nAb) evaluation (figure 1). The Ebola virus 
glycoprotein-specific T-cell response was measured by 
intracellular cytokine staining (appendix p 4).
The Ebola virus neutralisation assay was done with 
infectious Ebola virus (Makona and Mayinga lineages) in 
biosafety level 4 facilities (Bernhard Nocht Institute for 
Tropical Medicine, Hamburg, Germany), using pre-
vaccination and post-vaccination blood samples from 
20 adult vaccinees (ten per group). Post-vaccination 
samples in the ChAd3-EBO-Z group were selected pro-
portionally from the highest (three samples), lowest 
(three samples), and intermediate (four samples) 
concentrations of available anti-glycoprotein Ebola virus 
IgG antibodies. Serum from Ebola virus disease survivors 
and WHO reference serum for neutralisation assays 
were used as positive controls (appendix p 4).
The anti-ChAd3 neutralisation assay used a serotype-
specific, replication-incompetent adenovirus, which has 
an inserted luciferase reporter gene, as described 
previously26,27 and as detailed in the appendix (p 5). The 
threshold for positivity was set at a 90% nAb titre of 200.
Outcomes
The primary objective was to assess safety and reacto-
genicity of a single intramuscular dose of ChAd3-EBO-Z 
in healthy adults. The secondary objective was to evaluate 
humoral immunogenicity of a single intramuscular dose 
of ChAd3-EBO-Z, in terms of anti-glycoprotein Ebola 
virus IgG antibody responses as measured by ELISA.
The following primary endpoints were evaluated for a 
subcohort (approximately 750 participants per group): 
occurrence of solicited local or general adverse events 
within 7 days post-vaccination and unsolicited adverse 
events within 30 days post-vaccination; haema tological 
and biochemical abnormalities at screening, days 3, 6, 
30, months 6 and 12, and additionally at month 6 +6 days 
and month 6 +30 days for the placebo/ChAd3-EBO-Z 
group; and clinical symptoms of thrombocytopenia 
(day 0–6). Serious adverse events (up to month 12) were 
evaluated as the primary outcome for all participants. 
Secondary outcomes were anti-glycoprotein Ebola virus 
antibody concentrations (measured by ELISA) at day 0, 
day 30, month 6, and month 12; and percentage of 
seronegative or seropositive participants for anti-
glycoprotein Ebola virus antibodies at day 0, day 30, 
month 6, and month 12. The secondary outcomes are 
further detailed in the appendix (p 2).
Persistence of antibodies, Ebola virus, and Ebola Sudan 
virus-glycoprotein specific T-cell responses, and nAb 
response against the ChAd3 vector, and further 
characterisation of immune response (Ebola virus nAb) 
after a single intramuscular dose of ChAd3-EBO-Z, were 
tertiary outcomes.
Statistical analysis
The study had no confirmatory objective and all 
analyses were descriptive. The target sample size of 
1500 participants per group was calculated to fulfil the 
primary safety objective, according to consultations with 
regulatory authorities coordinated by WHO. The actual 
proportions associated with a 90% probability of observing 
a certain number of serious adverse events within a group 
of 1500 participants are provided in the appendix (p 5).
Safety analyses were done on the as treated cohort, and 
immunogenicity analyses in the per-protocol cohort.
Demographic characteristics were summarised by 
group using descriptive statistics for the total vaccinated 
cohort, which included all participants with at least 
one documented study dose administration. Safety and 
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Figure 1: Study design
Dashed outlines indicate study contacts (home visit or phone call). Screening and day 0 visits were allowed to take place on the same day (allowed interval 0–30 days). Solid outlines (month 6 + 6 days 
and month 6 + 30 days) indicate visits only for participants in the subcohort for follow-up of adverse events and assessment of humoral immunity in the placebo/ChAd3-EBO-Z group.*These visits 
were only for participants in the subcohort for follow-up of adverse events and assessment of humoral immunity. †Blood samples only taken from participants in the subcohort for follow-up of 
adverse events and assessment of humoral immunity. ‡Blood samples were only taken from participants in the subcohort for cell-mediated immunity.
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tabulated as the percentage of participants with a specific 
adverse event and its 95% CI (Clopper-Pearson method). 
We focused on the post-day 0 vaccination results since 
pooling of data after day 0 and month 6 ChAd3-EBO-Z 
vaccination did not alter conclusions regarding the 
vaccine’s reactogenicity.
Immunogenicity was assessed for the per-protocol 
cohort comprising participants who met all eligibility 
criteria, had received at least one study dose according 
to protocol procedures and their random assignment, 
complied with protocol-defined procedures and intervals, 
and for whom data concerning immunogenicity endpoint 
measures were available.
For humoral immune response, seropositivity rates with 
exact 95% CIs were calculated by group. Geometric mean 
concentrations were tabulated, with 95% CIs as obtained 
by exponential transformation (base 10) of 95% CIs for 
the mean of the log-transformed concentrations. Mean 
geometric fold increases (MGI) were calculated as 
exponential transformation of the mean of the log 
transformed ratio of post-dose assay result to baseline 
assay result.
Vaccine responses to the antigen (with exact 95% CIs) 
were calculated. The same analyses were done by 
baseline anti-glycoprotein Ebola virus ELISA serological 
status. The relationship between day 30 anti-glycoprotein 
antibody ELISA titres (log values) and baseline anti-
ChAd3 neutralisation titres (log values) was evaluated 
using a post-hoc linear regression, and expressed in 
terms of the correlation coefficient (r²). For the cell-
mediated immunity response, the frequency of specific 
CD4+ and CD8+ T cells was summarised for each study 
group using descriptive statistics.
All analyses were done using SAS, version 9.4. An 
unmasked independent data monitoring committee 
monitored safety and reactogenicity data. This study is 
registered with www.clinicaltrials.gov, NCT02485301 and 
was done in parallel with a phase 2 trial in children, 
NCT02548078.25
Role of the funding source
GlaxoSmithKline Biologicals SA was involved with 
study design, data collection, data analysis, data inter-
pretation, and writing of the report. GlaxoSmithKline 
Biologicals SA paid for costs associated with the develop-
ment and publishing of this manuscript. All authors 
had full access to all the data in the study, reviewed and 
commented on a draft version of the manuscript, and gave 
final approval before submission. All authors had final 
responsibility for the decision to submit for publication.
Results
Between July 22, 2015, and Dec 10, 2015, of 3770 screened 
adults, 3030 were randomly assigned to one of the 
study groups. The total vaccinated cohort included 
3013 participants (1509 [50·1%] in the ChAd3-EBO-Z 
group and 1504 [49·9%] in the placebo/ChAd3-EBO-Z 
group; figure 2). Demographic and baseline character-
istics were similar between the two groups (table 1). Most 
participants (3006 [99·8%]) were of African heritage, 
1626 (54·0%) were male, and the median age was 
29 years (range 18–85). 104 (3·4%) participants were 
withdrawn from the study (46 in the ChAd3-EBO-Z 
group and 58 in the placebo/ChAd3-EBO-Z group), 
mostly because of moving from the study area or loss to 
follow-up. One participant in the placebo/ChAd3-EBO-Z 
group erroneously received two doses of ChAd3-EBO-Z 
(at day 0 and month 6); the participant was excluded 
from immunogenicity analyses but did not report any 
serious adverse events after the second vaccination.
Figure 2: Trial profile
The ChAd3-EBO-Z group received ChAd3-EBO-Z vaccine at day 0, while the placebo/ChAd3-EBO-Z group received 
saline placebo at day 0 and ChAd3-EBO-Z at month 6. *11 excluded for: two laboratory results outside acceptable 
ranges; six non-compliance with visit schedule; one pre-existing prohibited medical condition; one received 
prohibited concomitant medication; one vaccine not administered per protocol. †Three excluded for: one laboratory 
results outside acceptable ranges; one received prohibited concomitant medication; one vaccine not administered 
per protocol. ‡19 excluded for (some for more than one reason): three laboratory results outside acceptable ranges; 
one excluded from the total vaccinated cohort; nine non-compliance with visit schedule; four pre-existing prohibited 
medical condition; one received prohibited concomitant medication; seven vaccine not administered per protocol. 
§Five excluded for (some for more than one reason): one excluded from the total vaccinated cohort; 
two non-compliance with visit schedule; two pre-existing prohibited medical condition; one vaccine not 
administered per protocol.
1516 assigned to ChAd3-EBO-Z 
8 no study dose administered
3030 enrolled and randomly assigned
3770 adults assessed for eligibility
1508 assigned to ChAd3-EBO-Z
           and included in as randomised
           analysis
738 included in humoral
         immunogenicity subcohort
11 excluded*
110 included in cell-mediated
 immunity subcohort 
  3 excluded†
1509 received ChAd3-EBO-Z and
            included in as treated
             analysis
2 given placebo/ChAd3-EBO-Z
   at day 0
1514 assigned to placebo/
            ChAd3-EBO-Z 
9 no study dose administered
740 ineligible
1505 assigned to placebo/
           ChAd3-EBO-Z and included
           in as randomised analysis 
733 included in humoral
         immunogenicity subcohort
19 excluded‡
109 included in cell-mediated
  immunity subcohort
    5 excluded§
1504 received placebo/
            ChAd3-EBO-Z and included
            in as treated analysis
3 given ChAd3-EBO-Z at
    day 0
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Solicited local symptoms within 7 days post-day 0 were 
reported by 358 (48%) of 748 participants in the ChAd3-
EBO-Z group and 61 (8%) of 751 in the placebo/ChAd3-
EBO-Z group. The most common soli cited injection site 
symptom post-day 0 vaccination was pain, reported by 
356 (48%) participants in the ChAd3-EBO-Z group and 
57 (8%) participants in the placebo/ChAd3-EBO-Z group; 
most cases were grade 1 (figure 3). Grade 3 injection site 
pain was reported by three (<1%) of 748 ChAd3-EBO-Z 
recipients, all cases of which resolved within 4 days.
Solicited general symptoms within 7 days post-day 0 
were reported by 450 (60%) of 748 participants in 
the ChAd3-EBO-Z group and 208 (28%) of 751 in the 
placebo/ChAd3-EBO-Z group. The most common soli-
cited general symptom was headache, reported by 
345 (46%) of 748 in the ChAd3-EBO-Z group and 
136 (18%) of 751 in the placebo/ChAd3-EBO-Z group; 
most were grade 1 (figure 3). Grade 3 headache was 
reported by ten (1%) of 748 in the ChAd3-EBO-Z group 
and four (1%) of 751 in the placebo/ChAd3-EBO-Z group; 
nine cases in the ChAd3-EBO-Z group and three cases 
in the placebo/ChAd3-EBO-Z group were considered 
related to study vaccination by the investigator. Fever was 
reported by 106 (14%) of 748 in the ChAd3-EBO-Z group 
and 24 (3%) of 751 in the placebo/ChAd3-EBO-Z group, 
with a median duration of 1 day (SD 1·40, range 1–7) for 
the ChAd3-EBO-Z group and 1 day (1·32, 1–6) for the 
placebo/ChAd3-EBO-Z group. The highest incidence of 
fever occurred on day 1 post-vaccination (appendix p 6). 
Grade 3 fever was reported for three (<1%) of 748 
ChAd3-EBO-Z recipients and was considered vaccination-
related for two (<1%) participants.
At least one unsolicited adverse event within 30 days 
post-day 0 vaccination was reported by 123 (16%) of 
749 participants in the ChAd3-EBO-Z group and 
119 (16%) of 751 in the placebo/ChAd3-EBO-Z group 
(appendix p 7); most events were mild in severity. 
Eight severe unsolicited adverse events (two chills, two 
pain, one arthralgia, one myalgia, one back pain, and one 
polyuria) were reported by seven (1%) ChAd3-EBO-Z 
recipients; all events were considered vaccination-related. 
Two (<1%) participants in the placebo/ChAd3-EBO-Z 
group reported two unsolicited adverse events (ovarian 
cyst and tinnitus), of which one (tinnitus) was considered 
vaccination-related. The most frequently reported 
unsolicited adverse events in the ChAd3-EBO-Z group 
were malaria (n=31, 4%), rhinitis (n=16, 2%), increased 
alanine aminotransferase (n=15, 2%), anaemia 
(n=13, 2%), and dizziness (n=9, 1%); and in the placebo/
ChAd3-EBO-Z group were malaria (n=31, 4%), rhinitis 
(n=25, 3%), increased alanine aminotransferase 
(n=16, 2%), and increased blood creatinine (n=12, 2%).
Changes in laboratory safety parameters are presented 
in the appendix pp 7–8 (ie, investigations and blood and 
lymphatic system disorders). Most events were mild in 
severity except two (<1%) ChAd3-EBO-Z recipients had 
moderate anaemia, one (<1%) participant in the placebo/
ChAd3-EBO-Z group had a moderate increase in alanine 
aminotransferase, and one (<1%) participant in the 
placebo/ChAd3-EBO-Z group had a moderate increase 






Adverse events and 
humoral immunity
749 (49·6%) 751 (49·9%)
Cell-mediated 
immunity
112 (7·4%) 114 (7·6%)
Age, years
Mean age 32·4 (18–85) 33·0 (18–84)
18–40 1136 (75·3%) 1133 (75·3%)
41–60 325 (21·5%) 327 (21·7%)
>60 48 (3·2%) 44 (2·9%)
Gender
Women 697 (46·2%) 690 (45·9%)
Men 812 (53·8%) 814 (54·1%)
Health-care worker
Yes 174 (11·5%) 176 (11·7%)
No 1335 (88·5%) 1328 (88·3%)
Race
African heritage or 
African American
1505 (99·7%) 1501 (99·8%)
American Indian or 
Alaskan native
1 (0·1%) 0
Asian 3 (0·2%) 3 (0·2%)
Japanese heritage 1 (0·1%) 0
Southeast Asian 
heritage
2 (0·1%) 3 (0·2%)
Ethnicity
American Hispanic or 
Latino
6 (0·4%) 11 (0·7%)
Not American Hispanic 
or Latino
1503 (99·6%) 1493 (99·3%)
Baseline childbearing potential of female participants
Yes 547 (78·5%) 541 (78·4%)
No 150 (21·5%) 149 (21·6%)
Hysterectomy, bilateral 
ovariectomy, or current 
tubal ligation
21 (3·0%) 13 (1·9%)
Post-menopausal or 
pre-menarche
129 (18·5%) 136 (19·7%)
Physical characteristics
Baseline height, cm 169·4 (142–205) 169·2 (145–200)
Baseline weight, kg 69·6 (40·0–122·0) 69·2 (38·9–142·5)
Country
Cameroon 85 (5·6%) 85 (5·7%)
Mali 821 (54·4%) 823 (54·7%)
Nigeria 167 (11·1%) 163 (10·8%)
Senegal 436 (28·9%) 433 (28·8%)
Data are n (%) or mean (range). Baseline was the last non-missing assessment 
(scheduled or unscheduled) before the first vaccination at day 0. *Adults that 
were vaccinated at day 0 and month 6 with ChAd3-EBO-Z vaccine included.
Table 1: Baseline characteristics of the total vaccinated cohort
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thrombocyte concentrations were observed post-day 0 
vaccination without notable differences between groups 
(appendix p 9).
No clinically meaningful thrombo cytopenia within 
7 days post-day 0 vaccination was reported for either 
group. Five mild cases of thrombo cytopenia were 
reported as unsolicited adverse events within 30 days 
post-day 0 vaccination (appendix pp 7–8); two additional 
cases were reported post-month 6 ChAd3-EBO-Z 
vaccination. Pooled data after day 0 and month 6 
ChAd3-EBO-Z vaccination did not differ from the post-
day 0 reactogenicity and safety results (data not shown).
At least one serious adverse event was reported for 
11 (1%) of 1509 participants in the ChAd3-EBO-Z group, 
and 18 (1%) of 1504 participants in the placebo/ChAd3-
EBO-Z group of which three (<1%) occurred post-month 
6 ChAd3-EBO-Z vaccination (appendix p 10); none were 
considered vaccination-related. Four participants died 
during the study. Two deaths occurred in the ChAd3-
EBO-Z group: a 52-year-old man died after craniocerebral 
injury due to a motor vehicle accident 147 days post-
vaccination; and a 29-year-old woman died 239 days post-
vaccination due to rifampicin-induced liver injury. 
Two participants from the placebo/ChAd3-EBO-Z group 
who had received only the placebo, died during the study: 
one 26-year-old woman died 286 days after placebo 
administration due to postpartum haemorrhage, and 
one 19-year-old mother experienced the sudden death of 
a neonate with unknown cause, 413 days after placebo 
administration. None of these events were considered to 
be related to study vaccination.
46 (3·3%) of 1387 women reported pregnancies. 
One pregnant woman received placebo despite positive 
pregnancy urine test at screening; 14 women became 
pregnant after receiving ChAd3-EBO-Z, and 32 after 
recei ving placebo (these women did not receive 
ChAd3-EBO-Z at month 6). The overall number of 
livebirths with no apparent congenital anomaly was 
37 (80%) of 46 (12 [92%] of 13 in the ChAd3-EBO-Z group 
and 25 [76%] of 33 in the placebo/ChAd3-EBO-Z group); 
four elective and two spontaneous abortions were 
reported. One pregnancy resulted in early neonatal 
death, as detailed above under fatal serious adverse 
events.
No participants reported suspected Ebola virus disease 
during this study. At day 0 (before vaccination), 25% of 
participants had anti-glycoprotein Ebola virus IgG anti-
body concentrations of 36·11 EU/mL or greater (table 2). 
A reverse cumulative curve of the distribution of anti-
glycoprotein Ebola virus IgG antibody concentrations 
at day 0 for participants with values of 36·11 EU/mL 
or greater at baseline (appendix p 11), showed that 
approximately 35% of participants had anti-glycoprotein 
concentrations greater than 200 EU/mL and 10% of 
participants had anti-glycoprotein concentrations greater 
than 1000 EU/mL. The proportion of participants with 
concentrations of 36·11 EU/mL or greater in the 
ChAd3-EBO-Z group was more than 97% at all post-
vaccination timepoints, regardless of pre-vaccination 
concentrations (table 2). Anti-glycoprotein Ebola 
virus IgG antibodies persisted up to 12 months post-
vaccination in the ChAd3-EBO-Z group, with 99% having 
Figure 3: Solicited injection site and general symptoms
Data refer to the total vaccinated subcohort for adverse events and immunogenicity (day 0–6). Gastrointestinal symptoms included nausea, vomiting, diarrhoea, 
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antibody concentrations of 36·11 EU/mL or greater 
(figure 4, table  2). Anti-glycoprotein Ebola virus IgG 
antibody geometric mean concentration in the 
ChAd3-EBO-Z group tended to be higher in participants 
with baseline titres of 36·11 EU/mL or greater (table 2). 
Anti-glycoprotein antibody responses at 30 days and 
6 months post-ChAd3-EBO-Z vaccination in the 
placebo/ChAd3-EBO-Z group (thus, study month 6 
+30 days, and study month 12) were similar to those 
observed at day 30 and month 6 in the ChAd3-EBO-Z 
group (table 3). At 30 days post-day 0 vaccination, 
anti-glycoprotein antibody response was observed for 
92% of ChAd3-EBO-Z vaccinees, compared with 8% 
of participants who received placebo/ChAd3-EBO-Z 
(table 3). A graphical representation of anti-glycoprotein 
Ebola virus IgG immune responses is provided in the 
appendix (p 12).
Anti-glycoprotein ELISA MGI were highest at day 30 
post-vaccination in the ChAd3-EBO-Z group, decreased 
until month 6, but remained stable by month 12, 
regardless of baseline serostatus. While MGI point 
estimates were much higher in adults with baseline anti-
glycoprotein antibody concentrations of less than 
36·11 EU/mL, the MGI value for adults with baseline 
concentrations of 36·11 EU/mL or greater was still 7·4 at 
day 30 (table 2). In the placebo/ChAd3-EBO-Z group, 
MGI values at 30 days and 6 months post-ChAd3-EBO-Z 
vaccination (month 6 +30 days and month 12) were 
similar to those observed at day 30 and month 6 in the 
ChAd3-EBO-Z group (figure 4).
Ebola virus glycoprotein-specific CD4+ and CD8+ T-cell 
responses were observed at day 30 post-vaccination 
(appendix pp 13–14). Ebola virus-specific CD4+ T-cell 
response was observed in 15 (36%) of 42 ChAd3-EBO-Z 
recipients at day 30 and 21 (21%) of 100 at month 6, 
compared with three (8%) of 39 at day 30 and 14 (14%) 
of 97 at month 6 in the placebo/ChAd3-EBO-Z 
group. Moderate increases of the proportion of Ebola 
virus-specific CD4+ T-cells were observed at 30 days 
post-ChAd3-EBO-Z vaccination, particularly for CD4+ 
T-cells co-expressing two (interleukin 2 [IL2] and tumour 
necrosis factor α [TNFα]) or three cytokines (IL-2, TNFα 
and interferon γ [IFNγ]). An Ebola virus-specific CD8+ 
T-cell response was observed in nine (21%) of 
42 ChAd3-EBO-Z recipients at day 30, and 15 (15%) of 
100 at month 6, compared with one (3%) of 39 at day 30 
and 16 (16%) of 97 at month 6 in the placebo/ChAd3-EBO-Z 
group. When calculated for all participants from the cell-
mediated immunity subcohort with results available at 
the relevant visit, the median percentage of Ebola virus 
Total Baseline <36·11 EU/mL Baseline ≥36·11 EU/mL
GMC (95% CI) ≥36·11 EU/mL 
n/N1 (%)
MGI (95% CI) GMC (95% CI) ≥36·11 EU/mL 
n/N1 (%)




Day 0 32 (29–35) 186/737 (25%) NA 18 (18–18) 0/551 NA 174 (146–207) 186/186 (100%) NA
Day 30 900 (824–983) 712/731 (97%) 28·1 (25·2–31·2) 795 (719–880) 530/545 (97%) 44·1 (39·8–48·7) 1300 (1089–1550) 181/185 (98%) 7·4 (6·1–9·1)
Month 6 459 (429–491) 716/721 (99%) 14·3 (13·0–15·9) 438 (406–472) 537/539 (100%) 24·3 (22·5–26·2) 528 (455–612) 178/181 (98%) 3·0 (2·5–3·7)
Month 6 +30 days NA NA NA NA NA NA NA NA NA
Month 12 432 (402–465) 687/693 (99%) 13·6 (12·3–15·1) 405 (373–440) 520/523 (99%) 22·4 (20·7–24·4) 528 (454–615) 167/170 (98%) 2·9 (2·4–3·6)
Placebo/ChAd3-EBO-Z group
Day 0 32 (29–35) 184/733 (25%) NA 18 (18–18) 0/549 NA 176 (148–208) 184/184 (100%) NA
Day 30 35 (32–38) 203/726 (28%) 1·1 (1·0–1·2) 21 (20–23) 46/543 (9%) 1·2 (1·1–1·3) 147 (120–180) 157/183 (86%) 0·9 (0·7–1·0)
Month 6 27 (25–28) 127/701 (18%) 0·8 (0·8–0·9) 20 (19–21) 23/522 (4%) 1·1 (1·1–1·1) 63 (51–77) 104/179 (58%) 0·4 (0·3–0·4)
Month 6 +30 days* 861 (796–931) 669/674 (99%) 26·6 (23·9–29·6) 798 (730–872) 501/504 (99%) 44·1 (40·4–48·2) 1079 (916–1270) 168/170 (99%) 6·1 (4·9–7·5)
Month 12* 566 (530–604) 670/672 (100%) 16·4 (14·8–18·2) 526 (488–568) 501/503 (100%) 27·2 (25·0–29·6) 700 (616–795) 169/169 (100%) 3·7 (3·1–4·5)
EU=ELISA units. GMC=geometric mean concentration. MGI=mean geometric fold increase. N1=total number of participants with results available at the relevant visit in the relevant analysis cohort per treatment 
group. NA=not applicable. Responders were defined as having a three-times increase in anti-glycoprotein antibody concentrations compared with baseline for participants with baseline concentration 
≥36·11 EU/mL, or post-baseline seroconversion (appearance of antibody concentration ≥36·11 EU/mL) for baseline-seronegative participants. *The placebo/ChAd3-EBO-Z group received the ChAd3-EBO-Z 
vaccine at month 6; the results from month 6 + 30 days and month 12 should therefore be compared with the results of day 30 and month 6 in the ChAd3-EBO-Z group.
Table 2: Seropositivity and anti-glycoprotein Ebola virus antibody GMC
Figure 4: Anti-glycoprotein ELISA mean geometric fold increase
The ChAd3-EBO-Z group received the ChAd3-EBO-Z vaccine at day 0, and the 
placebo/ChAd3-EBO-Z group received the ChAd3-EBO-Z vaccine at month 6. 
The placebo/ChAd3-EBO-Z results from month 6 + 30 days and month 12 should 
therefore be compared with the results of day 30 and month 6 in the ChAd3-EBO-Z 
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glycoprotein-specific CD8+ T cells expressing simul-
taneously IFNγ and TNFα (associated with protection in 
a preclinical non-human primate model) was 0·003% 
at day 0, 0·010% at day 30, 0·012% at month 6, and 
0∙008% at month 12 post-ChAd3-EBO-Z vaccination, 
and remained unchanged (0∙0002% at each timepoint) 
for placebo. The percentage of Ebola virus glycoprotein-
specific CD4+ and CD8+ T-cells expressing at least one 
cytokine, and co-expression profiles of Ebola Zaire 
antigen-specific CD4+ and CD8+ T cells are shown in the 
appendix (pp 13–14).
At day 30 post-ChAd3-EBO-Z vaccination, the MGI for 
Ebola virus glycoprotein-specific CD4+ T cells expressing 
at least one cytokine was 2∙4 (95% CI 1∙9–3∙0); and for 
CD8+ T cells, 2∙5 (1∙8–3∙3). At month 6 post-vaccination, 
MGI had decreased to 1∙6 (95% CI 1∙3–1∙9) for CD4+ 
cells and 1∙3 (1∙0–1∙8) for CD8+ cells. Groups are pooled 
together because of the low number of participants 
with available results (CD4+, 111 and 134 participants at 
30 days and 6 months post-ChAd3-EBO-Z; CD8+, 
110 and 131 participants at 30 days and 6 months 
post-ChAd3-EBO-Z). No Ebola Sudan virus glycoprotein-
specific CD4+ or CD8+ T-cell responses were observed 
(data not shown).
None of the 20 selected participants (appendix p 4) had 
detectable neutralising antibodies against Ebola virus, 
with the lowest dilution titre that could be tested being 
1/4 for the Makona lineage and 1/8 for the Mayinga 
lineage. No differences were observed between pre-
vaccination and post-vaccination sera (data not shown). 
Positive controls were able to neutralise Ebola virus.
A ChAd3 nAb response above the threshold of 
positivity was observed in 32 (29%) of 110 participants 
at day 0, 63 (58%) of 108 at day 30, and 36 (35%) of 103 
at month 6 in the ChAd3-EBO-Z group, and 32 (29%) of 
109 participants at day 0, 28 (27%) of 103 at day 30, and 
24 (25%) of 98 at month 6 in the placebo/ChAd3-EBO-Z 
group. In participants with pre-vaccination ChAd3 nAb 
titres greater than the threshold of positivity, ELISA 
antibody response to Ebola glycoprotein remained well 
above baseline until month 6. Based on a post-hoc 
linear regression analysis, ChAd3 nAb concentrations 
were found to explain only a small proportion (r²=3%) 
of the ELISA anti-glycoprotein antibody titre variability. 
Post-day 30 in the ChAd3-EBO-Z group, anti-glyco-
protein ELISA geometric mean con centrations were 
670 (95% CI 475–844) in participants with baseline 
ChAd3 nAb greater than 200, and 850 (701–1030) in 
participants with baseline ChAd3 nAb less than 200 
(appendix p 15). Anti-glycoprotein ELISA geometric 
mean concentrations by baseline anti-ChAd3 neutrali-
sation status and baseline anti-glycoprotein ELISA 
seropositivity are shown in the appendix (p 16); 
however, only ten participants had baseline con-
centrations greater than cutoff for both anti-glycoprotein 
and anti-ChAd3. Groups were pooled together for in-
creased accuracy, because of the low number of 
participants with available results.
Discussion
This phase 2 study provides a robust description of 
the safety, reactogenicity, and immunogenicity of the 
investigational ChAd3-EBO-Z vaccine, administered as a 
single intramuscular dose to healthy adults. The vaccine 
had an acceptable safety and reactogenicity profile, in 
line with observations from phase 1 studies.22–24
The most common solicited injection site symptom 
was pain (48%), with a similar incidence as the 
rVSV-EBOV phase 1 trial (57%)28 and the rVSV-EBOV 
ring vaccination trial (47% at 0–30 min post-vaccination, 
5·7% at 31 min–3 days post-vaccination).20 The most 
common solicited general symptom was headache (46%), 
similar to the rVSV-EBOV phase 1 trial (47%)28 but higher 
than in rVSV-EBOV ring vaccination trial (27% up to 
30 min post-vaccination, 25% at 31 min–3 days post-
vaccination).20 Similar headache rates were observed for 
Total Baseline <36·11 EU/mL Baseline ≥36·11 EU/mL
n/N1 Percentage (95% CI) n/N1 Percentage (95% CI) n/N1 Percentage (95% CI)
ChAd3-EBO-Z group
Day 30 672/730 92% (89·9–93·1) 530/545 97% (95·5–98·5) 142/185 77% (70·0–82·6)
Month 6 633/720 88% (85·3–90·2) 537/539 100% (98·7–100) 96/181 53% (45·5–60·5)
Month 6 +30 days NA NA NA NA NA NA
Month 12 608/693 88% (85·1–90·1) 520/523 99% (98·3–99·9) 88/170 52% (44·0–59·5)
Placebo/ChAd3-EBO-Z group
Day 30 57/726 8% (6·0–10·1) 46/543 9% (6·3–11·1) 11/183 6% (3·1–10·5)
Month 6 28/701 4% (2·7–5·7) 23/522 4% (2·8–6·5) 5/179 3% (0·9–6·4)
Month 6 +30 days* 621/674 92% (89·8–94·1) 501/504 99% (98·3–99·9) 120/170 71% (63·1–77·3)
Month 12* 603/672 90% (87·2–91·9) 501/503 100% (98·6–100) 102/169 60% (52·6–67·8)
EU=ELISA units. N1=total number of participants with results available at the relevant visit in the relevant analysis cohort per treatment group. NA=not applicable. 
*The placebo/ChAd3-EBO-Z group received the ChAd3-EBO-Z vaccine at month 6; the results from month 6 + 30 days and month 12 should therefore be compared with the 
results of day 30 and month 6 in the ChAd3-EBO-Z group.
Table 3: Anti-Ebola virus humoral immune response for anti-glycoprotein Ebola virus responders
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licensed adjuvanted recombinant zoster vaccine (51% in 
adults 50–59 years), which had an even higher incidence 
of injection site pain (88%).29
While fever was reported by 14% of adults in the 
ChAd3-EBO-Z group, most cases were mild (≤38∙5°C). 
All cases were short-lived and occurred immediately 
post-vaccination, which might help distinguish post-
vaccination fever from fever due to Ebola virus disease in 
cases of mass vaccine deployment.
The potential effect of the vaccine on thrombocyte 
counts was assessed. Results confirmed the absence of 
decreasing trends in thrombocyte counts post-vaccination, 
and absence of clinically meaningful thrombocytopenia.
The vaccine induced an anti-glycoprotein Ebola virus 
antibody response at day 30, confirming findings from 
phase 1 trials, which used other ELISA assays.22–24 We 
showed persistence of immune response up to 12 months 
post-vaccination, similar to results obtained in Liberia 
with the same vaccine and dose.30 A persistent immune 
response is promising and desirable considering the 
length of time often required to control Ebola virus 
epidemics.
Pre-vaccination ChAd3 nAb concentrations explain 
only a small proportion of ELISA anti-glycoprotein 
antibody titre variability at day 30. Further investigation 
is needed to evaluate the effect of ChAd3 nAbs on the 
ELISA anti-glycoprotein response.
Ebola virus CD4+ and CD8+ T-cell responses observed 
after single vaccination were of low amplitude, although 
MGI at 30 days post-ChAd3-EBO-Z vaccination reached 
2∙4 for Ebola virus glycoprotein-specific CD4+ T cells 
expressing at least one cytokine, and 2∙5 for CD8+ T cells. 
Similar low amounts of T-cell responses were previously 
observed after ChAd3-EBO-Z priming. Nevertheless, 
these res ponses were substantially boosted after 
vaccination with a modified vaccinia Ankara (MVA) vector 
encoding Ebola virus glycoprotein, even if T cells were not 
detectable at day 7 post-ChAd3-EBO-Z vaccination.19,23,24 
This obser vation suggests a true priming potential of the 
response obtained after single ChAd3-EBO-Z vaccination. 
Besides large-scale single vaccination approaches to 
contain epidemics in general populations, prime-boost 
approaches could be considered for specific populations 
requiring more durable protection (eg, health-care, front-
line, and funeral workers).
Although individuals with known previous Ebola virus 
or Ebola Sudan virus disease were excluded from 
participation, approximately 25% had anti-glycoprotein 
Ebola virus IgG antibody concentrations of 36·11 EU/mL 
or greater before vaccination. This observation might 
result from potential assay limitations as the technical 
cutoff was determined using samples from a UK 
population. We recognise a risk of overestimation of 
anti-glycoprotein Ebola virus ELISA response, assuming 
that the cutoff is too sensitive for our study population. 
Nevertheless, the assay proved to clearly distinguish 
between pre-vaccinated and post-vaccinated individuals 
(both with and without high pre-vaccination ELISA 
reactivity). Even in ChAd3-EBO-Z vaccinees with baseline 
anti-glycoprotein antibody concentrations of 36·11 EU/mL 
and greater, MGI was 7∙4 at 30 days post-vaccination.
In addition to potential assay limitations, we cannot 
completely rule out the hypothesis of some natural 
immunity against Ebola antigens or cross-antigens.31 
Zaire Ebola-specific antibodies have already been 
observed pre-vaccination30,32,33 and might be ascribed to 
subclinical infections, and environmental or other factors. 
Sero positivity assessments outside of trials34–37 and a 
serological survey testing oral swabs of asymptomatic 
household members of Ebola virus disease survivors 
confirmed existence of asymptomatic infection with 
Ebola virus, despite being uncommon.38
No nAb activity against Ebola virus was detected in our 
experimental conditions, including in samples with high 
ELISA anti-glycoprotein antibody activity. This finding 
contrasts with previous data showing nAb responses after 
single ChAd3-EBO-Z vaccination23 and could be the result 
of less sensitive assay conditions in our study (appendix 
pp 4–5). Other potential factors include that our evaluation 
was done in an African population, not a UK population,23 
and the small number of specimens available for 
evaluation. Of note, even in the previous study, responses 
were of low amplitude but were boosted after vaccination 
with Ebola virus glycoprotein-encoding MVA.23
No correlate of protection against Ebola virus disease 
has yet been established for ChAd3-EBO-Z immune 
responses, and we could not show efficacy of 
ChAd3-EBO-Z in other study settings due to the 
rarefaction of Ebola cases in these settings.30 Nevertheless, 
indirect evidence supports the protective potential of 
ChAd3-EBO-Z against Ebola virus disease, and hence a 
potential role in reactive vaccination to contain Zaire 
Ebola epidemics. ChAd3-EBO-Z was fully protective in 
non-human primate challenge experiments,14 at the same 
dose as used in the current study in humans. Moreover, 
in another study in Liberia using an assay with the same 
technical specification, ChAd3-EBO-Z has been shown to 
induce anti-glycoprotein Ebola virus responses like those 
observed with the rVSV vaccine candidate,30 for which 
efficacy was shown.20 Moreover, we detected Ebola virus 
glycoprotein-specific CD4+ and CD8+ T-cell responses; 
CD8+ T-cell responses are considered to play a crucial 
role in conferring protection after adenovirus-based 
vaccination in non-human primate challenge experi-
ments.14,39 Although the observed T-cell responses after a 
single dose were low, this response is likely to be highly 
boostable, as supported by findings from previous 
studies.23,24
A plain language summary contextualising the results 
and their potential clinical relevance is provided in the 
appendix (p 17).
These data support the acceptable safety and 
reactogenicity profile of ChAd3-EBO-Z in adults. We 
observed anti-glycoprotein Ebola virus IgG antibody and 
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Ebola virus glycoprotein-specific CD4+ and CD8+ T-cell 
responses 30 days after single-dose vaccination, with 
antibody responses persisting up to 12 months post-
vaccination. Long-term follow-up is needed for better 
characterisation of immunogenicity. The currently 
available information supports a role for single-dose 
vaccination in Ebola virus disease epidemic containment. 
The collected evidence, including a large and acceptable 
safety dataset in a wide study population (from the age of 
1 year, when combined with the parallel paediatric study) 
can contribute to further improvements in ChAd3-EBO-Z 
and further vaccine development. Future development 
steps should concentrate on multi valent approaches, 
including Sudan and Marburg strains in the vaccine. 
Moreover, the focus should be on prime-boost approaches 
using ChAd3-based vaccine as priming and MVA-based 
vaccine as the booster, supported by encouraging results 
with this approach in previous studies.
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